(Q34924442)

5 August 2017

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome (English)

1 reference

5 August 2017

9

R Champlin

1 reference

5 August 2017

6

S Giralt

1 reference

5 August 2017

L De Padua Silva

1

1 reference

5 August 2017

M de Lima

2

1 reference

5 August 2017

H Kantarjian

3

1 reference

5 August 2017

S Faderl

4

1 reference

5 August 2017

P Kebriaei

5

1 reference

5 August 2017

J Davisson

7

1 reference

5 August 2017

G Garcia-Manero

8

1 reference

5 August 2017

J-P Issa

10

1 reference

5 August 2017

F Ravandi

11

1 reference

5 August 2017

language of work or name

English

0 references

publication date

19 January 2009

1 reference

Bone Marrow Transplantation

5 August 2017

1 reference

5 August 2017

43

1 reference

5 August 2017

11

1 reference

5 August 2017

839-843

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2008.400

5 August 2017

0 references

cites work

Clinical issues in the management of patients with myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Gene silencing in cancer in association with promoter hypermethylation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

CpG island methylator phenotype in cancer

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Methylation profiling in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.400

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.400

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference